Unraveling the Safety Aspects of JAK Inhibitors

RATIONALE

The new pharmacological class of JAK inhibitors has already consolidated an important clinical efficacy for patients with rheumatoid arthritis, both when JAKi are used early, i.e., as the first line after the failure of csDMARDs, and in patients failing multiple lines of bDMARDs. Along with efficacy, however, some aspects related to possible safety issues peculiar to this class of drugs emerged. Surely, the growing experience derived from the use of drugs and real-life data will lead to further definition of any problems and better support the clinician decisions about the better therapeutic strategy combining efficacy and safety for each RA patient.
Tackling and deepening the problem from a clinical and biological point of view and in a multidisciplinary way, can help us to better address therapeutic decisions in clinical practice.
Based on these considerations, the aim of this project is to address the main concerns associated with the use of JAK inhibitors, in particular cardiovascular, thrombotic and infectious, from a clinical and biological point of view and in an integrated way with the experts in managing these clinical aspects, to have the most updated skills and knowledge in JAKi management.
 

SCIENTIFIC DIRECTORS

STEFANO ALIVERNINI - ROMA
ELISA GREMESE - ROMA
 

FACULTY

FABIO CACCIAPAGLIA - BARI
ANTONELLA CINGOLANI - ROMA
VALERIO DE STEFANO - ROMA
MARCELLO GOVONI - FERRARA
SIMONE PERNIOLA - ROMA
LUCA QUARTUCCIO - UDINE
FRANCESCA ROMANA SPINELLI - ROMA
VINCENZO VENERITO - BARI